ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-mutant Calreticulin Monoclonal Antibody INCA033989

Its studies are mostly in Myeloproliferative Disorders · Thrombocythemia, Essential, led by Incyte.

Drug pageAnti-mutant Calreticulin Monoclonal Antibody INCA033989: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 29, 20264 company-led studies, 4 open or runningNext primary completion: Feb 29, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Incyte44 open or runningphase 3since May 29, 2026Jun 21, 2023Feb 29, 2028phase 1 · NCT05936359

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 21, 2023First study: phase 1 study in Myeloproliferative DisordersFirst studyNCT05936359 · 160 enrolled · Australia, Canada, Denmark and more
  2. Aug 30, 2023Phase 1 study in Myeloproliferative DisordersNCT06034002 · 290 planned · United States
  3. Feb 26, 2026Phase 1 study in Healthy ParticipantsNCT07448155 · 108 enrolled · United States
  4. May 29, 2026Phase 3 study in Thrombocythemia, EssentialPhase 3 reachedNCT07623200 · 426 planned · United States, Australia, Austria and more

Ahead

  1. Nov 14, 2026Primary completion: phase 1 study in Healthy ParticipantsNCT07448155
  2. Feb 29, 2028Primary completion: phase 1 study in Myeloproliferative DisordersNCT05936359
  3. Oct 29, 2028Primary completion: phase 1 study in Myeloproliferative DisordersNCT06034002
  4. Jun 15, 2029Primary completion: phase 3 study in Thrombocythemia, EssentialNCT07623200

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07623200Thrombocythemia, Essential · United States, Australia, Austria and more3RecruitingJun 15, 2029426
NCT07448155Healthy Participants · United States1Active, not recruitingNov 14, 2026108
NCT06034002Myeloproliferative Disorders · United States1RecruitingOct 29, 2028290
NCT05936359Myeloproliferative Disorders · Australia, Canada, Denmark and more1Active, not recruitingFeb 29, 2028160

How it is read

Names in the registry

  • “INCA033989”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.